Intellia Therapeutics (NASDAQ:NTLA) Given New $14.00 Price Target at Citigroup

Intellia Therapeutics (NASDAQ:NTLA) had its price target increased by Citigroup from $12.00 to $14.00 in a research report sent to investors on Friday,Benzinga reports. Citigroup currently has a neutral rating on the stock.

A number of other brokerages have also weighed in on NTLA. BMO Capital Markets lowered their target price on Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a research note on Friday, January 10th. The Goldman Sachs Group restated a “sell” rating and issued a $9.00 target price on shares of Intellia Therapeutics in a research note on Friday. William Blair reiterated a “neutral” rating and issued a $14.00 price objective on shares of Intellia Therapeutics in a research report on Monday, November 18th. StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a research report on Friday, November 8th. Finally, Barclays lowered their price objective on Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating for the company in a research report on Friday, November 8th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $42.12.

Intellia Therapeutics Stock Performance

Shares of NASDAQ:NTLA opened at $10.09 on Friday. Intellia Therapeutics has a twelve month low of $8.96 and a twelve month high of $34.87. The firm has a market cap of $1.03 billion, a PE ratio of -1.85 and a beta of 1.80. The business has a fifty day moving average of $10.90 and a 200-day moving average of $15.72.

Insider Activity

In other news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the transaction, the chief executive officer now owns 941,115 shares in the company, valued at $11,462,780.70. The trade was a 2.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold 29,000 shares of company stock worth $352,551 in the last 90 days. Corporate insiders own 3.20% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

Several institutional investors have recently modified their holdings of NTLA. GF Fund Management CO. LTD. bought a new position in shares of Intellia Therapeutics during the 4th quarter valued at about $25,000. Sterling Capital Management LLC lifted its stake in Intellia Therapeutics by 866.2% in the 4th quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock valued at $37,000 after acquiring an additional 2,867 shares in the last quarter. Whipplewood Advisors LLC bought a new stake in Intellia Therapeutics in the 4th quarter valued at approximately $40,000. Resona Asset Management Co. Ltd. bought a new stake in Intellia Therapeutics in the 4th quarter valued at approximately $43,000. Finally, Jones Financial Companies Lllp lifted its stake in Intellia Therapeutics by 140.9% in the 4th quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock valued at $45,000 after acquiring an additional 2,280 shares in the last quarter. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.